SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 21, 2015--
Exelixis, Inc. (Nasdaq:EXEL) today announced that it plans to offer,
subject to market and other conditions, 20,000,000 shares of its common
stock in an underwritten public offering. The company expects to grant
the underwriters a 30-day option to purchase up to an additional
3,000,000 shares of common stock in connection with the offering. All of
the shares of common stock in the offering will be sold by Exelixis.
Cowen and Company, William Blair and Stifel are acting as bookrunners
for the offering. The offering is being conducted by means of a
prospectus supplement filed as part of a shelf registration statement
previously filed with the Securities and Exchange Commission (SEC) on
Form S-3.
This announcement does not constitute an offer to sell or a solicitation
of an offer to buy nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. This press release is
being issued pursuant to and in accordance with Rule 134 under the
Securities Act of 1933, as amended. Any offer, if at all, will be made
only by means of a prospectus, including a prospectus supplement,
forming a part of the effective registration statement. Copies of the
preliminary prospectus supplement and base prospectus relating to the
offering may be obtained, when available, from Cowen and Company, LLC
(c/o Broadridge Financial Services., 1155 Long Island Avenue, Edgewood,
NY 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax:
631-254-7140); William Blair & Company, L.L.C., Attention Prospectus
Department, 222 West Adams Street, Chicago, Illinois 60606, Phone:
800-621-0687, Email: prospectus@williamblair.com;
and Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, California 94104, Phone:
415-364-2720, Email: syndprospectus@stifel.com.
Exelixis intends to file a preliminary prospectus supplement relating to
the offering with the SEC, which will be available along with the
prospectus filed with the SEC in connection with the shelf registration
statement, on the SEC’s website at http://www.sec.gov.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer.
Forward-Looking Statements
This announcement contains forward-looking statements, including
statements relating to Exelixis’ expectations regarding the completion,
timing and size of the proposed public offering. These statements are
subject to significant risks and uncertainties, actual results could
differ materially from those projected and Exelixis cautions investors
not to place undue reliance on the forward-looking statements contained
in this release. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the public
offering. There can be no assurance that Exelixis will be able to
complete the public offering on the anticipated terms, or at all. Risks
and uncertainties relating to Exelixis and its business can be found in
the “Risk Factors” section of Exelixis’ Form 10-Q, filed with the SEC on
April 30, 2015, and in the preliminary prospectus supplement related to
the proposed offering to be filed with the SEC. Exelixis undertakes no
duty or obligation to update any forward-looking statements contained in
this release as a result of new information, future events or changes in
Exelixis’ expectations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150721006558/en/
Source: Exelixis, Inc.
Exelixis, Inc.
Chris Senner, 650-837-7240
Chief
Financial Officer
csenner@exelixis.com
Susan
Hubbard, 650-837-8194
Investor Relations & Corporate
Communications
shubbard@exelixis.com